#USA #Parkinson's Disease #Brenig Therapeutics #BT-267 #Somerville, Massachusetts

Brenig Therapeutics Expands Leadership and Pipeline

Brenig Therapeutics, a clinical-stage biotech firm specializing in AI-driven therapies for neurodegenerative diseases, recently made headlines by appointing David L. Lucchino as its new President and CEO, along with Tien Dam, M.D. as its Chief Medical Officer. This strategic shift in leadership comes at a crucial juncture for the company as it aims to broaden its pipeline and advance crucial drug development efforts.

Key Appointments Signal Growth

The announcements were made on July 10, 2025, as part of the company's ongoing efforts to position itself at the forefront of neurodegenerative disease treatment. David L. Lucchino brings more than 20 years of experience in the life sciences sector. His tenure includes co-founding Frequency Therapeutics, which focuses on restorative therapies, and serving as CEO of Semprus BioSciences and LaunchCyte. His enthusiasm for joining Brenig is evident as he stated, “I'm honored to join Brenig as we work to unlock new therapies for patients living with neurodegenerative diseases.”

Similarly, Dr. Tien Dam, previously with Neumora Therapeutics and a notable leader in clinical development at Biogen, will play a crucial role in enhancing the company's neurology pipeline. She expressed optimism about the prospects of BT-267, the lead candidate targeting Parkinson's disease, and its preclinical and early clinical profile. “BT-267's promise in addressing key challenges in Parkinson's drug development is significant,” she remarked.

Expansion of Therapeutics Pipeline

Along with the new appointments, Brenig announced the acquisition of BT-409, a pre-clinical candidate designed to be a best-in-class inhibitor for NLRP3. This compound, which is intended for the treatment of Parkinson's disease, may also hold therapeutic potential for other neuro-inflammatory conditions like Alzheimer's and multiple sclerosis. The safety profile of BT-409, deemed promising in preclinical models, sets the stage for upcoming Phase 1 safety studies.

Dr. Iain Dukes, Chairman of the Board, articulated his excitement about the new leadership and acquisitions. He emphasized the need for innovative therapies in the space of neurodegenerative diseases and mentioned both Lucchino's exceptional track record and Dam's clinical expertise as invaluable assets during a time of expansion.

A Focused Approach to Parkinson's Disease

Brenig's lead candidate, BT-267, showcases a selective and brain-penetrant profile in inhibiting LRRK2, a significant protein involved in Parkinson's pathology. The drug aims to enhance CNS exposure while limiting peripheral exposure, which could minimize side effects associated with traditional therapies. The hope is that by addressing the underlying causes of the disease, BT-267 could provide a disease-modifying treatment that slows down or potentially halts Parkinson's progression.

Both BT-267 and BT-409 are reflections of Brenig Therapeutics’ commitment to merging cutting-edge AI methodologies with clinical advancements to develop solutions that meet the needs of affected patients.

As Brenig Therapeutics sets forth on this journey of leadership and innovation, the healthcare community is watching closely, hopeful that these new initiatives will lead to effective treatments for neurodegenerative diseases and transform patient outcomes.